bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract LB-508: A GSA-NMP1 conjugate: An NIR-activatable fluorescence imaging agent to detect peritoneal ovarian cancer metastases
Authors: Alexander Vinita M. , Sano Kohei , Yu Zhanqian , Nakajima Takahito , Choyke Peter L. , Ptaszek Marcin , Kobayashi Hisataka 
Published: August 2012

Abstract
Purpose: There is a need to improve detection of peritoneal ovarian cancer metastases before and during surgery. Previous designs of activatable GSA-fluorophore probes, which target lectin receptors, have used only visible range dyes conjugated to GSA. However, activatable agents emitting fluorescence in the NIR range are advantageous because NIR photons have deeper in vivo tissue penetration and lower background autofluorescence than those emitting in the visible range. An NIR-activatable GSA fluorophore pair can be synthesized using the dye NMP1. This NMP1 dye has two unique absorption peaks (in green and NIR wavelength ranges) with a single NIR emission peak of 780nm. NMP1 thus has two different Stoke's shifts that have the potential to allow separate imaging of tumor nodules both at the surface and at depths below the surface. Experimental Design: GSA was conjugated with 2 NMP1 molecules to create a self-quenching complex (GSA-NMP1). The activation magnitude of GSA-NMP1 was validated by adding 10% SDS. Flow cytometry, fluorescence microscopy, and in vivo spectral fluorescence imaging were carried out to compare GSA-NMP1 with GSA-IR800 (an always on control agent with similar emission to NMP1) in terms of intracellular activation and abilities to allow detection of small ovarian cancer implants in mice models. Sensitivity and specificity of GSA-NMP1 for implant detection were determined by co-localizing NMP1 emission spectra with red fluorescent protein expressed constitutively in SHIN3 tumor implants. Image processing in Java was used to subtract spectral images, with resulting images theorized to show tumor nodules at a depth below the surface. Results: The fluorescence signal of GSA-NMP1 can be activated ∼100-fold and was specifically yielded after internalization into SHIN3 cells 3h after incubation. Submillimeter ovarian cancer implants in the peritoneal cavity were clearly detectable in vivo with spectral fluorescence imaging. Among 555 peritoneal lesions, the sensitivity and specificity for GSA-NMP using NIR and green excitation light, were 75%/92% and 91%/92% for lesions ∼0.8 mm or greater in diameter, respectively. Image processing suggests that nodules at a depth below the small bowel are imaged only with GSA-NMP1 by subtraction of the two excitation images. Conclusions: GSA-NMP1 is useful in imaging peritoneal ovarian cancer metastases, located both superficially and deep in the abdominal cavity.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-508. doi:1538-7445.AM2012-LB-508
Abstract LB-51: Breast cancer survivorship in women younger than 45 years
Authors: Preusse Courtney 
Published: August 2012

Abstract
Since opening its doors in 1975, the Fred Hutchinson Cancer Research Center has served as a world leader in advancing the prevention, diagnosis and treatment of cancer and related diseases as causes of human suffering and death. Breast cancer has long been a strong focus of the center. Our Consortium Breast Cancer Research Program initiated over 15 years ago, fosters novel and interdisciplinary work amongst world-renowned scientists and the clinical community that examines the physical, psychological, social and economic effects of cancer treatment. Moreover, our survivorship program, as part of the LIVESTRONG Survivorship Center of Excellence Network, promotes health-protective behaviours and helps survivors and doctors understand, prevent and manage these effects. Despite this wealth of knowledge, I submit that there is a sheer lack of credible breast health resources and there are countless missed opportunties to improve upon surveillance of a sizeable yet largely underrepresented population due to perceived rarity of cancer in young women. Breast cancer knows no boundaries; it does not discriminate on the basis of age. Specific, unique and neglected concerns facing young women with breast cancer must be addressed through new directions in research; first, so as to represent the entire population of survivors rather than a subset and, second, to close critical gaps in knowledge.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-51. doi:1538-7445.AM2012-LB-51
Abstract LB-510: Longitudinal imaging of melanoma cancer cell metastasis in a preclinical model by bioluminescence, PET/CT, and MRI
Authors: Adiseshaiah Pavan P. , Stern Stephan T. , Patel Nimit L. , Ileva Lilia V. , Kalen Joseph D. , Haines Diana C. , McNeil Scott E. 
Published: August 2012

Abstract
Metastasis of cancer cells from the primary tumor are a leading cause of poor prognosis and death from cancer. The lung is the most common organ for metastatic spread of cancer and leads to 20-50% of cancer-related deaths. Early detection of cancer metastasis to the lung and other organs could be beneficial in disease management. In animal studies, most secondary-site disseminated tumors are evaluated by optical imaging, and gross examination at necropsy and subsequent histopathological analysis. These techniques are limited in that they do not offer the ability to monitor animals during the course of tumor development, and optical microscopy may have inadequate field of view (3-D morphometrics) for thorough tumor evaluation. Noninvasive imaging allows for serial imaging of the same animal, with the ability to repeat measurements in real-time to enhance the observation of disease progression and therapeutic response. Here, we compared the multimodal noninvasive whole-body imaging techniques bioluminescence, 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography (PET)/ computed tomography (CT), and magnetic resonance imaging (MRI) to image lung metastasis development following intravenous injection of melanoma cells (B16-F10 melanoma cell line expressing luciferase gene) in C57BL/6. By bioluminescence imaging, tumor cell localization in the lungs was evident as early as 3 days (1 x 105 photons/sec; total flux) post cancer cell inoculation and steadily increased through the end of week four (1 x 108 photons/sec; total flux). The increase in the lung tumor burden was confirmed by lung histopathology. As it was difficult to de-convolve the effects of photon flux spreading from lungs over other organs, other metastatic sites were not evaluated by bioluminescence. CT and 18F-FDG-PET are used clinically to image lung metastasis and offer excellent resolution of anatomical and metabolic details of cancer cells. We were able to image metastatic nodules in the lung by PET/CT at week four, which showed a strong correlation with histopathology analysis. [18F]FDG-PET/CT also revealed metastasis in the kidney and mesentery and were confirmed by histopathology. T2-weighted MRI at week 4 identified several lung tumors and metastatic cancers in the abdomen. A comparison of [18F]FDG/PET at week 4 to MRI and CT displayed several highly metabolic regions within the tumors. Histopathology confirmed the metastatic spread of the melanoma cells to the lung, mediastinum, kidney, and mesentery. Funded by NCI contract No. HHSN261200800001E.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-510. doi:1538-7445.AM2012-LB-510
Abstract LB-512: A novel rotational Raman imaging device for early cancer detection
Authors: Garai Ellis , Zavaleta Cristina , Sensarn Steve , Mandella Michael , Gambhir Sanjiv S. , Contag Christopher H. 
Published: August 2012

Abstract
A novel Raman imaging device that is capable of rotationally scanning hollow structures has been developed to be used in conjunction with tumor targeting Surface enhanced Raman scattering (SERS) nanoparticles. SERS nanoparticles can act as excellent contrast agents in that they offer ultra high sensitivity, and multiplexing capabilities due to the unique spectral signatures associated with them. One key advantage of multiplexing includes the ability to utilize several targeted SERS probes to target and localize a multitude of unique biomarkers associated with a specific disease, and effectively increasing cancer specificity. The device can potentially be used to distinguish a variety of tissues of interest in the colon such as: flat lesions, varying types of adenomas and carcinomas. There are also applications beyond the colon, such as the esophagus, stomach, oral cavity and bladder. In addition, multiplexing can allow for real-time functional imaging. A 45-degree scanning mirror, actuated with micro-motor, is used to perform circumferential scans of the lumen of the colon at a rate of 1 revolution per second and a spatial resolution or approximately 1.5 mm. The device is able to be used with currently available endoscopes by inserting it into the working channel of an endoscope. The use of many (36) multi-mode fibers is used to increase the flexibility of the fiber bundle so that it can be inserted and used in a fully articulating endoscope while still being able to collect a sufficient amount scattered Raman light. When in the circumferential scanning mode, American National Standards Institute (ANSI) regulations will allow us to increase the laser illumination power to about 580 mW at a scan rate of 60rpm, resulting in a detection limit of approximately 1 pM of SERS nanoparticles. One of the key features of our Raman device is that it has been designed for efficient use over a wide range of working distances. This is necessary to accommodate for imperfect centering of the device within the colon, as well as variable working distances due to folds and bends within the colon. These techniques could allow endoscopists to distinguish between normal and cancerous tissues instantly, as well as to identify flat lesions that are easily missed during conventional screening endoscopy. After a suspicious region has been identified, the rotating mirror can be held at a certain angle, and used to help guide biopsies or resection of tissues in real-time.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-512. doi:1538-7445.AM2012-LB-512
Abstract LB-515: Guanine nucleotide exchange factor Dock7 expression is increased in human glioblastoma and mediates tumor cell invasion.
Authors: Murray David W. , Didier Sebastien , Chan Amanda , Paulino Vincent , Tran Nhan , Byrne Annette , Symons Marc 
Published: August 2012

Abstract
Glioblastoma multiforme (GBM), the most common and deadly adult brain malignancy, is an incurable disease with an average life expectancy of 14 months following diagnosis. GBM morbidity is primarily due to its rapid growth, neovascularization and invasion throughout the brain. Recently, anti-VEGF therapies approved in this indication have paradoxically been shown to stimulate the invasive behavior of GBM. Members of the Rho family of small GTPases have been established as important mediators of GBM cell invasion. These proteins are activated by guanine nucleotide exchange factors (GEFs). In the current study, we sought to identify GEFs that are up-regulated in high-grade glioma and which may be of functional importance in human GBM. In this study we have shown that that Dock7, a GEF that can mediate signaling of Rac1 and Cdc42 Rho GTPases is up-regulated in human GBM tissue in comparison with normal brain. We have further demonstrated that Dock7 silencing by RNA-interference inhibits invasion of U87 and SNB19 GBM cells into ex vivo brain slices. Dock7 silencing inhibits Hepatocyte Growth Factor (HGF)-induced cell invasion in a 3D in vitro assay. HGF is known to strongly stimulate GBM cell invasiveness and both HGF and its receptor c-MET have been shown to be up-regulated in high- versus low-grade gliomas. Interestingly, we have also shown that Dock7 binds to c-MET in an HGF-dependent manner and that this interaction requires the GAB1 adaptor protein. Dock7 silencing reduced HGF-induced activation of Rac1 and consistent with this, we have shown that Dock7 silencing results in the inhibition of HGF-induced lamellipodia formation in GBM cells. Finally Dock7 was shown to be activated in an HGF-dependant manner, using Rac1-G15A pull-down assay. In summary, our data suggests a role for Dock7 in GBM cell invasion thus, Dock7 may present a potential therapeutic target in the management of invasive GBM, in particular in the adjuvant setting in combination with anti-VEGF therapies.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-515. doi:1538-7445.AM2012-LB-515
Abstract LB-517: EIF5A2, A downstream target of PI3K/Akt pathway, Is an adverse prognostic marker of melanoma patient survival by increasing cell invasion
Authors: Khosravi Shahram , Wong Ronald P.C. , Martinka Magdalena , Li Gang 
Published: August 2012

Abstract
Human cutaneous melanoma is a life-threatening skin cancer due to its invasive nature and high metastatic potential, leading to poor prognosis for melanoma patients. However, the mechanisms for melanoma invasion and metastasis are poorly understood. Human eukaryotic translation initiation factor 5A2 (EIF5A2) has been shown to be associated with tumor progression in multiple types of cancers. We examined EIF5A2 expression in 459 melanocytic lesions at different stages using tissue microarray and immunohistochemistry and analyzed the correlations between EIF5A2 expression and clinicopathologic parameters and patient survival. We found that positive EIF5A2 staining was significantly increased in primary melanomas compared to dysplastic nevi (P=0.002), and further increased in metastatic melanomas (P=0.036). EIF5A2 expression was correlated with melanoma thickness (P=0.0004) and was inversely correlated with overall and disease-specific 5-year survival of primary (P=0.008 and 0.007, respectively), especially low-risk (≤2.0mm) melanoma patients (P=0.026 and 0.044, respectively). We also examined the correlation between EIF5A2 and p-Akt protein expression and their role in regulating melanoma cell invasion. Combining the TMA data sets for EIF5A2 and p-Akt, we found that positive EIF5A2 staining directly correlated with strong p-Akt expression (P=0.026). Additionally, overexpression of PTEN or inhibition of p-Akt or ILK significantly reduced EIF5A2 expression. EIF5A2 overexpression also increased melanoma cell invasion and MMP-2 activity. We for the first time showed that the expression of EIF5A2, a downstream target of PI3K/Akt pathway, is significantly increased during melanoma invasion and is inversely correlated with patient survival, suggesting that EIF5A2 may be used as a potential therapeutic target for melanoma.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-517. doi:1538-7445.AM2012-LB-517
Abstract LB-52: Relentless in the fight against blood cancer: the Leukemia & Lymphoma Society
Authors: Patterson Harriet A. 
Published: August 2012

Abstract
WHO WE ARE: The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. Founded in 1949, we are relentless in pursuit of our mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. WHAT WE DO: Investing in blood cancer research: LLS has invested more than $814 million in research, approximately $76.6 million in fiscal year 2011 alone. Programs like the Specialized Center of Research (SCOR), and our Translational Research Program have directly contributed to many breakthrough cancer treatments. Research funded by LLS has led or contributed to advances such as chemotherapy, bone marrow and stem cell transplantation and new, targeted oral therapies. Providing critical information and support for patients and their families: We made 7.1 million contacts with patients, caregivers and healthcare professionals in fiscal year 2011, Advocating for issues impacting blood cancer patients: With more than 56,000 advocacy volunteers throughout the country, our voice is being heard by those responsible for legislation to fund blood cancer research and educational programs. WHY: An estimated 1,012,533 people in the United States are living with, or are in remission from, leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma or myeloma.Approximately every four minutes, someone new is diagnosed with blood cancer. Approximately every 10 minutes, someone dies. Leukemia causes more deaths than any other cancer among children, adolescents and young adults under the age of 20. Lymphomas are the most common blood cancers and incidence increases with age. The survival rate for myeloma is only 41.1 percent. Incidence is more than twice as high among African Americans as for all other races. WHO WE SERVE: In addition to our national headquarters in White Plains, NY, we have a network of 59 local chapters across the United States and Canada. Our constituents live in urban, suburban, and rural communities, seek treatment at large comprehensive cancer centers and community clinics, and represent cultures from around the world. We work in partnership with community organizations, treatment centers, and government agencies to deliver quality cancer support services and to reach as many patients as we can in our region. We also work in partnership with other oncology and health organizations to meets the needs of the underserved people within our community.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-52. doi:1538-7445.AM2012-LB-52
Abstract LB-520: PTPN14 interacts with and negatively regulates the oncogenic function of YAP
Authors: Liu Xiaojun , Yang Nuo , Figel Sheila A. , Wilson Kayla E. , Morrison Carl D. , Gelman Irwin H. , Zhang Jianmin 
Published: August 2012

Abstract
ABSTRACT The Hippo signaling pathway regulates cellular proliferation and survival, thus exerting profound effects on normal cell fate and tumorigenesis. The pivotal effector of this pathway is YAP, a transcriptional co-activator amplified in mouse and human cancers where it promotes epithelial-to-mesenchymal transition (EMT) and malignant transformation. Using IP Mass-spec analysis, we have identified a novel regulatory mechanism for the YAP oncogenic function via direct interaction with non-receptor tyrosine phosphatase 14 (PTPN14). PTPN14 interacts with YAP through PPxY domain, and overexpression of PTPN14 increases the inactive cytoplasmic form of YAP and decreases the transcriptional co-activator activity of YAP. Moreover, knockdown of PTPN14 induces nuclear retention of YAP and increases YAP-dependent cell migration. In summary, our study indicate a potential tumor-suppressor role for PTPN14 in the Hippo pathway and demonstrate a novel mechanism in YAP regulation.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-520. doi:1538-7445.AM2012-LB-520
Abstract LB-53: Cancer clinical trials: real answers, real options, real miracles, right here in west Michigan
Authors: Gavin Patrick 
Published: August 2012

Abstract
“Cancer survivors sharing clinical trial experiences to increase awareness and knowledge in the search for prevention and cure.” Our goal is to increase the awareness of cancer clinical trials available in West Michigan. The Patient Advisory Board for Clinical Research was formed to capture the passion that clinical trial participants possess in searching for a cure for a disease that has personally affected them. Fear often accompanies a cancer diagnosis. The vision is to replace fear with the knowledge that is brought through clinical trials. The Patient Advisory Board for Clinical Research's objective is to make cancer clinical trials information available and increase general public awareness of this treatment option.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-53. doi:1538-7445.AM2012-LB-53
Abstract LB-56: My journey as a breast cancer survivor, from diagnosis to advocate
Authors: Morrow Jeannette 
Published: August 2012

Abstract
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-56. doi:1538-7445.AM2012-LB-56